Ty Affleck, MD
Family Practice · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 38 years
- Virginia Commonwealth University, School of Medicine, 1988
Offices
1 location
Hospitals listed: Petaluma Valley Hospital · Providence Santa Rosa Memorial Hospital · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Affleck’s office at (707) 546-9400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Petaluma Valley HospitalPetaluma, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Petaluma Valley Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 6 the same, 1 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.31 (0.23 to 2.39) · 147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.44 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.6 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.7 · 57 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 533 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,427 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,398 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.65) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.56 to 3.98) · 202 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.61 (0 to 18.36) · 49 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.16 (0.85 to 9.47) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.25) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.37 (0 to 1.41) · 1,184 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 6.1 · 26 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.308 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.6 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -3 · 143 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 131 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 52 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.8 to 17.8) · 364 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 138 cases | No different | Jan 2024 – Dec 2024 |
What patients said (246 patients answered, 23% of those asked)
| Cleanliness | 5 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 85% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$74,733
Medicare paid this office $74,733 for 244 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 216 | $54,526 | $100 |
| New patient visit (45+ min) | 61 | $7,538 | $124 |
| Aspiration and/or injection of fluid from large joint | 21 | $3,117 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,252 | $141 |
| Advance care planning, first 30 minutes | 16 | $927 | $58 |
See all 9 services
| Return visit (30+ min) | 216 | $54,526 | $100 |
| New patient visit (45+ min) | 61 | $7,538 | $124 |
| Aspiration and/or injection of fluid from large joint | 21 | $3,117 | $55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,252 | $141 |
| Advance care planning, first 30 minutes | 16 | $927 | $58 |
| Mri scan of lower spinal canal without contrast | 11 | $587 | $53 |
| X-ray of shoulder, minimum of 2 views | 12 | $90 | $8 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $50 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $15 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Aspiration and/or injection of fluid from large joint | 51 | 51 | 58 | 43 | 80 | 57 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
244 Original Medicare patients in 2024. Average age 73 · Women 53% · Health risk score 0.66. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 41% · Coronary heart disease 20% · Depression 16% · Diabetes 11% · Cancer 10% · Atrial fibrillation 10% · Heart failure 6% · Chronic kidney disease 5% · COPD 5% · Stroke 5%.
The office billed $167,588, Medicare allowed $102,241 and paid $74,733; for 1,098 services of 45 kinds; $2,463 of it was for drugs given in the office and $72,270 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 244 | 1,098 | 73 | 0.66 | $167,588 | $74,733 |
| 2023 | 232 | 1,046 | 72 | 0.65 | $151,708 | $73,227 |
| 2022 | 243 | 1,240 | 72 | 0.73 | $113,891 | $64,570 |
| 2021 | 350 | 4,239 | 72 | 0.73 | $203,028 | $124,446 |
| 2020 | 294 | 5,796 | 71 | 0.81 | $174,551 | $93,536 |
| 2019 | 310 | 6,139 | 71 | 0.73 | $169,544 | $90,633 |
| 2018 | 304 | 8,043 | 70 | 0.70 | $159,443 | $88,660 |
| 2017 | 269 | 1,520 | 70 | 0.70 | $146,826 | $77,296 |
| 2016 | 251 | 1,324 | 70 | 0.71 | $134,587 | $66,496 |
| 2015 | 231 | 1,228 | 70 | 0.72 | $129,752 | $68,253 |
| 2014 | 204 | 1,186 | 70 | 0.69 | $118,652 | $63,669 |
| 2013 | 197 | 1,267 | 70 | 0.79 | $114,015 | $64,429 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 9 services
| Return visit (30+ min) | 199 | $51,508 | $100 |
| New patient visit (45+ min) | 61 | $7,596 | $125 |
| Aspiration and/or injection of fluid from large joint | 21 | $4,443 | $56 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 13 | $3,947 | None |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 14 | $1,965 | $140 |
| Mri scan of leg joint without contrast | 11 | $597 | $54 |
| Annual depression screening, 5 to 15 minutes | 13 | $270 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 11 | $38 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $12 | None |
2022: 7 services
| Return visit (30+ min) | 216 | $45,056 | $94 |
| New patient visit (45+ min) | 52 | $6,649 | $128 |
| Aspiration and/or injection of fluid from large joint | 19 | $2,396 | $56 |
| Mri scan of lower spinal canal without contrast | 13 | $731 | $56 |
| Administration of influenza virus vaccine | 13 | $430 | $33 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 20 | $65 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $17 | None |
2021: 16 services
| Return visit (30+ min) | 301 | $82,326 | $99 |
| New patient visit (45+ min) | 74 | $9,683 | $131 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 34 | $4,944 | $145 |
| Aspiration and/or injection of fluid from large joint | 20 | $3,280 | $57 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 45 | $2,925 | $65 |
| Administration of influenza virus vaccine | 76 | $1,714 | $19 |
| Short return visit (20+ min) | 20 | $1,171 | $49 |
| Mri scan of lower spinal canal without contrast | 13 | $752 | $58 |
| Mri scan of leg joint without contrast | 13 | $719 | $55 |
| Annual depression screening, 5 to 15 minutes | 30 | $631 | $21 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 24 | $441 | $18 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 12 | $351 | $29 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 12 | $246 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $85 | None |
| X-ray of hip, 1 view | 12 | $80 | $7 |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $26 | None |
2020: 12 services
| Return visit (30+ min) | 234 | $60,025 | $82 |
| New patient visit (45+ min) | 59 | $6,516 | $110 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 30 | $3,831 | $128 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,746 | $54 |
| Short return visit (20+ min) | 30 | $1,749 | $53 |
| Administration of influenza virus vaccine | 55 | $972 | $18 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 13 | $793 | $61 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 33 | $646 | $20 |
| Annual depression screening, 5 to 15 minutes | 23 | $458 | $20 |
| Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | 11 | $322 | $29 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $76 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $16 | None |
2019: 14 services
| Return visit (30+ min) | 262 | $54,127 | $79 |
| New patient visit (45+ min) | 76 | $8,574 | $113 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 46 | $5,721 | $124 |
| Aspiration and/or injection of fluid from large joint | 19 | $2,537 | $50 |
| Mri scan of lower spinal canal without contrast | 21 | $1,431 | $62 |
| Pneumococcal vaccine, 23-valent | 12 | $1,311 | $109 |
| Short return visit (20+ min) | 16 | $877 | $55 |
| Mri scan of leg joint without contrast | 13 | $797 | $57 |
| Administration of influenza virus vaccine | 40 | $693 | $17 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 33 | $615 | $19 |
| Administration of pneumococcal vaccine | 18 | $312 | $17 |
| X-ray of knee, 4 or more views | 12 | $150 | $12 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 15 | $92 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $19 | None |
2018: 11 services
| Return visit (30+ min) | 255 | $49,585 | $76 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 11 | $12,334 | None |
| New patient visit (45+ min) | 89 | $10,461 | $118 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 32 | $3,822 | $119 |
| Aspiration and/or injection of fluid from large joint | 19 | $2,771 | $46 |
| Mri scan of lower spinal canal without contrast | 16 | $1,076 | $57 |
| Mri scan of leg joint without contrast | 16 | $873 | $55 |
| Administration of influenza virus vaccine | 31 | $666 | $21 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 30 | $560 | $19 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $86 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $17 | None |
2017: 13 services
| Return visit (30+ min) | 234 | $46,246 | $79 |
| New patient visit (45+ min) | 77 | $8,523 | $111 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 42 | $5,072 | $121 |
| Aspiration and/or injection of fluid from large joint | 24 | $3,661 | $46 |
| Pneumococcal vaccine, 13-valent | 12 | $2,243 | $187 |
| Short return visit (20+ min) | 15 | $1,309 | $48 |
| Mri scan of lower spinal canal without contrast | 13 | $851 | $61 |
| Mri scan of leg joint without contrast | 15 | $837 | $56 |
| Administration of influenza virus vaccine | 26 | $698 | $27 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 27 | $486 | $17 |
| X-ray of knee, 3 views | 14 | $359 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 21 | $181 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 22 | $27 | None |
2016: 12 services
| Return visit (30+ min) | 204 | $38,930 | $74 |
| New patient visit (45+ min) | 80 | $8,985 | $112 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 37 | $4,258 | $115 |
| Aspiration and/or injection of fluid from large joint | 22 | $3,222 | $45 |
| Short return visit (20+ min) | 20 | $1,097 | $31 |
| Mri scan of leg joint without contrast | 18 | $875 | $49 |
| Mri scan of lower spinal canal without contrast | 12 | $703 | $59 |
| Administration of influenza virus vaccine | 18 | $477 | $27 |
| X-ray of knee, 3 views | 13 | $317 | $23 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 19 | $224 | $12 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 18 | $145 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $27 | None |
2015: 12 services
| Return visit (30+ min) | 178 | $38,280 | $76 |
| New patient visit (45+ min) | 73 | $8,064 | $110 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 38 | $4,414 | $116 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 11 | $3,626 | None |
| Aspiration and/or injection of fluid from large joint | 18 | $3,175 | $47 |
| New patient visit (60+ min) | 11 | $1,766 | $161 |
| Short return visit (20+ min) | 14 | $1,593 | $57 |
| Administration of influenza virus vaccine | 22 | $612 | $27 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | 21 | $260 | $12 |
| X-ray of knee, 3 views | 11 | $172 | $13 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $105 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $22 | None |
2014: 8 services
| Return visit (30+ min) | 168 | $39,241 | $77 |
| New patient visit (45+ min) | 48 | $5,488 | $114 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 32 | $3,671 | $115 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,755 | $46 |
| Administration of influenza virus vaccine | 37 | $1,045 | $26 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 37 | $601 | $15 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 14 | $91 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 15 | $17 | None |
2013: 12 services
| Return visit (30+ min) | 172 | $42,297 | $79 |
| New patient visit (45+ min) | 51 | $6,256 | $123 |
| Aspiration and/or injection of fluid from large joint | 18 | $2,160 | $46 |
| Short return visit (20+ min) | 17 | $2,049 | $54 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $1,852 | $116 |
| Mri scan of lower spinal canal without contrast | 11 | $633 | $58 |
| Administration of influenza virus vaccine | 20 | $540 | $27 |
| X-ray of knee, 3 views | 11 | $309 | $28 |
| Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | 19 | $279 | $15 |
| X-ray of shoulder, minimum of 2 views | 11 | $235 | $21 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $86 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $23 | None |
Drugs they prescribed that Part D paid
$15,327
Pharmacies billed $15,327 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (15 of 603) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
551 generic and 52 brand-name prescriptions · $15,327 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Atorvastatin | 63 | $363 | $6 |
| Valacyclovir | 13 | $358 | $28 |
| Tamsulosin | 12 | $346 | $29 |
| Benazepril | 15 | $290 | $19 |
| Gabapentin | 21 | $178 | $8 |
See all 17 drugs
| Atorvastatin | 63 | $363 | $6 |
| Valacyclovir | 13 | $358 | $28 |
| Tamsulosin | 12 | $346 | $29 |
| Benazepril | 15 | $290 | $19 |
| Gabapentin | 21 | $178 | $8 |
| Levothyroxine | 31 | $175 | $6 |
| Escitalopram | 17 | $174 | $10 |
| Losartan | 11 | $136 | $12 |
| Amitriptyline | 11 | $119 | $11 |
| Lisinopril | 28 | $92 | $3 |
| Hydrochlorothiazide | 29 | $88 | $3 |
| Amlodipine Besylate | 33 | $57 | $2 |
| Prednisone | 16 | $56 | $4 |
| Allopurinol | 13 | $50 | $4 |
| Meloxicam | 13 | $28 | $2 |
| Zolpidem | 13 | $21 | $2 |
| Clonazepam | 11 | $16 | $1 |
Year by year
| 2024 | 603 | 93 | 3% (15) | 9% | $15,327 |
| 2023 | 615 | 94 | 3% (18) | None | $16,595 |
| 2022 | 532 | 102 | 2% (12) | None | $22,094 |
| 2021 | 222 | 61 | 13% (29) | None | $12,023 |
| 2020 | 253 | 61 | 21% (52) | None | $10,951 |
| 2019 | 160 | 57 | 19% (30) | None | $4,331 |
| 2018 | 190 | 60 | 12% (22) | None | $8,914 |
| 2017 | 261 | 59 | 17% (44) | 29% | $59,577 |
| 2016 | 295 | 55 | 16% (46) | None | $22,070 |
| 2015 | 295 | 54 | 15% (43) | None | $24,940 |
| 2014 | 348 | 60 | 7% (23) | None | $30,089 |
| 2013 | 275 | 60 | 6% (15) | None | $37,809 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Benazepril | 20 | $535 | $27 |
| Albuterol Sulfate Hfa | 14 | $444 | $32 |
| Atorvastatin | 41 | $442 | $11 |
| Tamsulosin | 13 | $379 | $29 |
| Levothyroxine | 30 | $356 | $12 |
| Lisinopril-Hydrochlorothiazide | 27 | $264 | $10 |
| Hydrochlorothiazide | 40 | $219 | $5 |
| Escitalopram | 11 | $218 | $20 |
| Losartan-Hydrochlorothiazide | 11 | $185 | $17 |
| Losartan | 12 | $158 | $13 |
| Prednisone | 20 | $140 | $7 |
| Amlodipine Besylate | 28 | $135 | $5 |
| Metoprolol | 14 | $133 | $10 |
| Lisinopril | 22 | $119 | $5 |
| Meloxicam | 19 | $83 | $4 |
| Gabapentin | 15 | $81 | $5 |
| Trazodone | 14 | $70 | $5 |
| Hydrocodone-Acetaminophen | 11 | $67 | $6 |
| Zolpidem | 14 | $58 | $4 |
| Carvedilol | 12 | $45 | $4 |
| Clonazepam | 14 | $37 | $3 |
2022: 14 drugs
| Levothyroxine | 50 | $521 | $10 |
| Tamsulosin | 16 | $375 | $23 |
| Losartan | 20 | $291 | $15 |
| Atorvastatin | 34 | $283 | $8 |
| Benazepril | 13 | $208 | $16 |
| Hydrochlorothiazide | 28 | $154 | $6 |
| Meloxicam | 22 | $128 | $6 |
| Simvastatin | 14 | $120 | $9 |
| Prednisone | 11 | $74 | $7 |
| Metoprolol | 11 | $74 | $7 |
| Amlodipine Besylate | 13 | $72 | $6 |
| Hydrocodone-Acetaminophen | 11 | $59 | $5 |
| Lisinopril | 17 | $51 | $3 |
| Clonazepam | 11 | $34 | $3 |
2021: 7 drugs
| Symbicort | 11 | $3,919 | $356 |
| Ventolin Hfa | 13 | $1,274 | $98 |
| Hydrocodone-Acetaminophen | 18 | $123 | $7 |
| Venlafaxine Hcl Er | 12 | $73 | $6 |
| Meloxicam | 18 | $52 | $3 |
| Prednisone | 11 | $51 | $5 |
| Clonazepam | 12 | $34 | $3 |
2020: 8 drugs
| Dextroamphetamine-Amphet Er | 11 | $588 | $53 |
| Diclofenac | 15 | $377 | $25 |
| Oxycodone-Acetaminophen | 12 | $319 | $27 |
| Hydrocodone-Acetaminophen | 18 | $192 | $11 |
| Tramadol | 22 | $153 | $7 |
| Prednisone | 13 | $85 | $7 |
| Meloxicam | 12 | $67 | $6 |
| Clonazepam | 12 | $30 | $3 |
2019: 3 drugs
| Dextroamphetamine-Amphet Er | 11 | $592 | $54 |
| Hydrocodone-Acetaminophen | 14 | $125 | $9 |
| Prednisone | 15 | $87 | $6 |
2018: 1 drug
| Prednisone | 14 | $94 | $7 |
2017: 5 drugs
| Forteo | 11 | $32,227 | $2,930 |
| Levothyroxine | 24 | $398 | $17 |
| Hydrocodone-Acetaminophen | 22 | $200 | $9 |
| Ultra-Fine Mini Pen Needle | 11 | $126 | $11 |
| Tramadol | 12 | $61 | $5 |
2016: 8 drugs
| Lantus | 18 | $4,573 | $254 |
| Oxycodone-Acetaminophen | 12 | $445 | $37 |
| Oxycodone | 11 | $273 | $25 |
| Gabapentin | 12 | $270 | $22 |
| Levothyroxine | 15 | $248 | $17 |
| Amitriptyline | 13 | $176 | $14 |
| Hydrocodone-Acetaminophen | 13 | $134 | $10 |
| Metformin | 15 | $86 | $6 |
2015: 9 drugs
| Lantus | 15 | $3,825 | $255 |
| Flector | 12 | $3,093 | $258 |
| Gabapentin | 15 | $502 | $33 |
| Pravastatin | 11 | $287 | $26 |
| Glipizide Er | 12 | $270 | $23 |
| Levothyroxine | 13 | $240 | $18 |
| Hydrocodone-Acetaminophen | 12 | $135 | $11 |
| Tramadol | 15 | $113 | $8 |
| Simvastatin | 13 | $110 | $8 |
2014: 8 drugs
| Celebrex | 11 | $4,951 | $450 |
| Levothyroxine | 28 | $529 | $19 |
| Escitalopram | 19 | $282 | $15 |
| Glipizide Er | 12 | $270 | $23 |
| Hydrocodone-Acetaminophen | 20 | $171 | $9 |
| Simvastatin | 17 | $138 | $8 |
| Metformin | 20 | $119 | $6 |
| Hydrochlorothiazide | 21 | $59 | $3 |
2013: 5 drugs
| Celebrex | 17 | $3,236 | $190 |
| Lantus | 13 | $2,143 | $165 |
| Escitalopram | 11 | $426 | $39 |
| Levothyroxine | 14 | $153 | $11 |
| Zolpidem | 14 | $72 | $5 |
Money from drug and device companies
$190 in 2024
| 2024 | 2 | 9 | None | $190 |
| 2023 | 3 | 19 | None | $409 |
| 2022 | 1 | 1 | None | $18 |
| 2021 | 2 | 2 | None | $62 |
| 2020 | 2 | 2 | None | $24 |
| 2019 | 4 | 4 | None | $64 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Qulipta | $149 | 8 payments
|
| Bioventus | Durolane | $41 | 1 payment
|
See all 9 published payments
| Abbvie | Meals · 2024-09-20 | Qulipta | $24 |
| Abbvie | Meals · 2024-09-16 | Qulipta | $33 |
| Abbvie | Meals · 2024-08-06 | Qulipta | $15 |
| Abbvie | Meals · 2024-07-11 | Qulipta | $10 |
| Abbvie | Meals · 2024-05-29 | Qulipta | $9 |
| Abbvie | Meals · 2024-05-23 | Qulipta | $24 |
| Abbvie | Meals · 2024-05-16 | Qulipta | $29 |
| Abbvie | Meals · 2024-05-07 | Qulipta | $6 |
| Bioventus | Meals · 2024-02-15 | Durolane | $41 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $409
| AbbVie | Qulipta | $295 | 17 payments
|
| Novo Nordisk | None | $99 | 1 payment
|
| DePuy Synthes Sales | Orthovisc | $15 | 1 payment
|
2022: $18
| Bioventus | Gelsyn-3 | $18 | 1 payment
|
2021: $62
| Abbott Laboratories | Proclaim Ipg | $48 | 1 payment
|
| DePuy Synthes Sales | Monovisc | $14 | 1 payment
|
2020: $24
| Bioventus | Durolane | $12 | 1 payment
|
| Bausch Health US | Wellbutrin | $12 | 1 payment
|
2019: $64
| Bioventus | Gelsyn 3 | $22 | 1 payment
|
| DePuy Synthes Sales | Orthovisc | $19 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $13 | 1 payment
|
| Orthofix Medical | Physio-Stim Osteogenesis Stimulator | $10 | 1 payment
|
Professional record
- NPI
- 1306941083
- Licence
- CA G073843
- Trained
- Virginia Commonwealth University, School of Medicine, 1988 · 38 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207QS0010X (207QS0010X)
- Mailing address
- 1255 N Dutton Ave, Santa Rosa, CA, 95401
- NPI first listed
- 2006-09-14
- NPI last updated
- 2009-05-11
This is when the NPI record was last certified, not a medical board exam.